$ARIA Recent Headlines Six stocks to watch 3:2
Post# of 102233
Six stocks to watch 3:27 p.m. Feb. 26, 2014 - The Trading Deck
6 stocks to watch 3:34 p.m. Feb. 12, 2014 - The Trading Deck
Ariad falls after wild ride upward, while Care.com holds on to its gains 9:02 p.m. Jan. 27, 2014 - Russ Britt
Apple green ahead of earnings; Caterpillar tops gainers 3:42 p.m. Jan. 27, 2014 - Sue Chang
Ariad shares jump nearly 30% on rumors of Big Pharma takeover 1:43 p.m. Jan. 24, 2014 - Russ Britt
5 charts to watch 3:52 p.m. Jan. 15, 2014 - The Trading Deck
Apple closes lower; B. of A. rises on analyst call 4:15 p.m. Jan. 2, 2014 - Wallace Witkowski
Apple gains on China Mobile deal; homebuilders rally 3:33 p.m. Dec. 23, 2013 - Wallace Witkowski
Suspension is lifted for Ariad's leukemia drug 6:33 a.m. Dec. 23, 2013 - MarketWatch.com
J.C. Penney and more of the year's most profitable shorts 3:23 p.m. Dec. 9, 2013 - blogs.marketwatch.com
Hewlett-Packard, a cyclical green light and why silver is in trouble 8:50 a.m. Nov. 26, 2013 - Shawn Langlois
Ariad takes another pounding after leukemia treatment is pulled 12:14 p.m. Oct. 31, 2013 - Russ Britt
H-P has best day in four months on upbeat outlook 3:34 p.m. Oct. 9, 2013 - Sue Chang
Ariad plummets 70% after drug test patients have serious clotting issues 10:38 a.m. Oct. 9, 2013 - Russ Britt
FDA places partial hold on Ariad's Iclusig trials 7:16 a.m. Oct. 9, 2013 - MarketWatch.com
Dan Loeb makes bet on Disney 7:06 p.m. Aug. 14, 2013 - David Benoit
Onyx share surge lifts several boats in biotech harbor, including ETFs 10:33 a.m. July 1, 2013 - Russ Britt
SAC Capital Advisors likes this pharma stock 3:24 p.m. April 18, 2013 - Insider Monkey
Ariad Pharma up 6% to $20.09 10:35 a.m. Dec. 17, 2012 - Steve Gelsi
FDA OKs Iclusig to treat rare types of leukemia 1:06 p.m. Dec. 14, 2012 - MarketWatch.com
Is Ariad Pharmaceuticals (ARIA) Stock a Solid Choice Right Now? - Tale of the Tape 8:55 a.m. Jan. 2, 2015 - Zacks.com
ARIAD & Angelini Team Up to Commercialize Iclusig in Europe - Analyst Blog 2:35 p.m. Dec. 31, 2014 - Zacks.com
Tuesday's #PreMarket Movers: Neuroderm, Microsoft, Medbox, Civeo And More 8:17 a.m. Dec. 30, 2014 - benzinga.com
Ariad inks Iclusig distribution deal for Central and Eastern Europe 7:55 a.m. Dec. 30, 2014 - Seeking Alpha
China Biotech Week In Review: Otsuka Buys Rights To ARIAD's Leukemia Drug 12:30 p.m. Dec. 28, 2014 - Seeking Alpha
Ariad Pharma inks commercialization deal in Asia 7:43 a.m. Dec. 23, 2014 - Seeking Alpha
Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve) 9:02 a.m. Dec. 19, 2014 - TheStreet.com
Mid-Afternoon Market Update: Oxford Industries Drops On Downbeat Results; Office Depot Shares Spike Higher 2:59 p.m. Dec. 11, 2014 - benzinga.com
Energy Stocks Pare Gains as Crude Oil Closes Below $60 For First Time in Five Years 2:52 p.m. Dec. 11, 2014 - TheStreet.com
Mid-Day Market Update: Dow Jumps Over 200 Points; Staples Shares Surge On Confirmation Of Stake By Starboard Value 11:40 a.m. Dec. 11, 2014 - benzinga.com
Will Ariad Pharmaceuticals (ARIA) Stock be Affected Today by This Analyst Action? 9:14 a.m. Dec. 11, 2014 - TheStreet.com
Morning Market Losers 8:57 a.m. Dec. 11, 2014 - benzinga.com
Analysts' Actions: AbbVie, Ariad, Lilly, Prologis, Toll Brothers 8:56 a.m. Dec. 11, 2014 - TheStreet.com
Top Analyst Upgrades and Downgrades: ARIAD, FedEx, Genpact, Suncor, Travelers, UPS and More 7:38 a.m. Dec. 11, 2014 - 247WallSt.com
UPDATE: Credit Suisse Downgrades Ariad Pharmaceuticals As Launch Metrics Are Still Weak 7:06 a.m. Dec. 11, 2014 - benzinga.com
Long-term follow up data for Iclusig positive 10:54 a.m. Dec. 9, 2014 - Seeking Alpha
ARIAD Reports Follow-up Data from Phase 1, PACE Trials of Ponatinib for T315I Mutation 6:37 a.m. Dec. 9, 2014 - benzinga.com
ARIAD Reports Long-term Safety, Efficacy Data of Ponatinib from Phase 2 Pace Trial: 83% of CP-CML Patients Achieved Response 6:36 a.m. Dec. 8, 2014 - benzinga.com
Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Post-Market Leader Stock 7:06 p.m. Dec. 3, 2014 - TheStreet.com
Hottest Healthcare Stocks Now – AVNR BIIB ARIA ACHN 6:15 a.m. Dec. 2, 2014 - InvestorPlace.com
Striking Deals on Street: New Research on State Investors, NCI, Ariad, Under Armour and Meadowbrook 9:20 a.m. Dec. 31, 2014 - PR Newswire - PRF
ARIAD Announces Commercialization Agreement for Iclusig in Seven Central and Eastern European Countries 7:35 a.m. Dec. 30, 2014 - BusinessWire - BZX
ARIAD To Present at The 33rd Annual J.P. Morgan Healthcare Conference 7:35 a.m. Dec. 22, 2014 - BusinessWire - BZX
Biotech Stocks Technical Insight -- ARIAD Pharma, Geron, PDL BioPharma, Cytori Therapeutics, and Navidea Biopharma 9:15 a.m. Dec. 18, 2014 - PR Newswire - PRF
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial 7:35 a.m. Dec. 8, 2014 - BusinessWire - BZX
Insider Trading Alerts for Hertz, Ariad Pharmaceuticals, J C Penney, Sirius XM, Apple, and Sunedison 8:45 a.m. Nov. 25, 2014 - PR Newswire - PRF
ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia 7:35 a.m. Nov. 24, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting 9:44 a.m. Nov. 6, 2014 - BusinessWire - BZX
ARIAD Reports Third Quarter 2014 Financial Results and Development Progress 7:36 a.m. Nov. 5, 2014 - BusinessWire - BZX
ARIAD to Present at the Stifel 2014 Healthcare Conference 7:35 a.m. Nov. 4, 2014 - BusinessWire - BZX
ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe 6:35 a.m. Oct. 24, 2014 - BusinessWire - BZX
Insider Trading Alerts for Micron, CSX, Ariad Pharmaceuticals, IBM, SinoCoking Coal and Coke Chemical, and MannKind 7:55 a.m. Oct. 21, 2014 - PR Newswire - PRF
Insider Trading Research for Halliburton, Ariad Pharmaceuticals, KeyCorp, GoPro, MannKind, and Plug Power 7:45 a.m. Oct. 20, 2014 - PR Newswire - PRF
Biotech Equities Technical Analysis - ARIAD Pharma, Novavax, Galena Biopharma, Geron, and Celldex Therapeutics 7:40 a.m. Oct. 15, 2014 - PR Newswire - PRF
ARIAD to Webcast Conference Call on Third Quarter 2014 Financial Results 6:35 a.m. Oct. 15, 2014 - BusinessWire - BZX
ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency 6:44 a.m. Oct. 10, 2014 - BusinessWire - BZX
ARIAD and Bellicum Announce Revised License Agreement for ARIAD’s Cell-Signaling Technology 6:35 a.m. Oct. 6, 2014 - BusinessWire - BZX
ARIAD’s AP26113 Receives FDA Breakthrough Therapy Designation For ALK+ Non-Small Cell Lung Cancer Resistant to Crizotinib 6:35 a.m. Oct. 2, 2014 - BusinessWire - BZX
ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer 6:35 a.m. Sept. 29, 2014 - BusinessWire - BZX